Rezolute, Inc.

On 9/15 Dr. Quan Dong Nguyen will be presenting "Safety and Efficacy of RZ402, a Novel, Orally Administered Plasma Kallikrein Inhibitor, from a Phase 2a Study in Patients with Diabetic Macular Edema” at The Retina Society Annual Meeting. Swing by and say hello!

We are thrilled the FDA has lifted the partial clinical holds on RZ358 for the treatment of congenital hyperinsulinism, allowing for U.S. inclusion in the ongoing global Phase 3 sunRIZE study: https://bit.ly/4cSDz8o

The Rezolute team is traveling to the 2024 Bradykinin Symposium in Berlin where Ian Yates will be presenting a poster titled, “Discovery of Highly Potent Plasma Kallikrein Inhibitors”, and Jeffrey Breit, Ph.D. will give a talk titled, “Novel Rezolute Plasma Kallikrein Inhibitors Prevent Edema in Animal Models”. Say hi to the team and learn more about our novel PKIs! https://lnkd.in/dBRdwED7

Rezolute management will be participating in the upcoming H.C. Wainwright & Co., LLC and Cantor Fitzgerald conferences. We hope to see you there! https://bit.ly/3TaEuKh

Today at Rezolute, we want to thank and shine a spotlight 🌟 on our three incredible interns who have been contributing their talents and energy throughout the summer at Rezolute!   Alfred Ceballos  Rezolute has provided me with a transformative and inspiring internship experience, setting a new benchmark for the kind of company I aspire to work with. The company’s unwavering commitment to innovation, collaboration, and respect has empowered me to take on leadership roles and contribute meaningfully to projects that truly matter. The supportive environment and open communication have challenged me to grow beyond my expectations. Being part of a team dedicated to excellence and making a difference has ignited my passion for the industry and solidified my ambition to contribute to Rezolute’s future success. Rezolute redefines what a truly exceptional company culture looks like, and I’m excited to continue growing with this remarkable team.   Carina Burruel  Rezolute has been an amazing vessel for exposure in the Biopharma field as well as mentorship for me. In my time at Rezolute, I have gained experience in navigation of a validated quality system and knowledge in Good Clinical and Manufacturing Practices. Everyone has been extremely willing to share their knowledge and insights as well as their journey's to their current positions. The integrity, skills, and passion the team has in making a difference in future patients lives, I believe will be a long-term motivator of Rezolute's. I am grateful for the opportunity to be apart of a team with a mission to bring transformative therapeutic care for rare diseases. Thank you Rezolute.   Ashley Lopez Chavez My experience at Rezolute has been truly remarkable! I’ve had the privilege of learning from Christen Baglaneas. Working under her guidance has provided me with a deep understanding of corporate operations, investor relations, and social media engagement, which has enriched my knowledge of the competitive landscape and market trends in the biopharmaceutical sector. This internship has allowed me to develop new skills, enhance my professionalism, and advance my future career interests! I’ve also had the pleasure of meeting many welcoming and supportive team members. I am truly grateful for the opportunity to be part of the Rezolute team and working alongside the organization's mission. Thank You Rezolute!   #interns #biotech #careerdevelopment 

We are thrilled to receive FDA clearance of our IND application for Phase 3 registrational study of RZ358 (ersodetug) in patients with tumor HI. This is the second rare disease program with RZ358 in late-stage development. Learn more about the trial and next steps: https://bit.ly/3SB513i

Rezolute on the road! Make sure to stop by and say hello if you're attending the 16th World Congress on Inflammation

Today we announced the close of a public offering with ~$60M in gross proceeds to fund corporate activities and post-Phase 3 planning for RZ358 in congenital hyperinsulinism, in addition to initiation and conduct of a potential late-stage, registrational, clinical study of RZ358 in patients with tumor hyperinsulinism: https://bit.ly/3VX6wei

An evidence-based estimate of congenital hyperinsulinism (cHI) birth prevalence is essential to improve diagnosis and patient management, to drive clinical research and the development of new treatments, and to inform public policy. With this recent publication we now have a better understanding of the true global impact of this rare disease. Thank you to the research and advocacy communities for their work on this important topic! https://bit.ly/3Vp0bXo

We’re thrilled to have been able to participate in this year’s Congenital Hyperinsulinism International Family Conference! Thank you to the families, physicians and colleagues that made this such a wonderful event, and for the continued support in developing new therapies to treat cHI.